The NeuVax clinical trial will be led by Elizabeth Mittendorf.
2011-0595(clinicaltrials.gov NCT No: NCT01479244)Title:PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive
Breast Cancer with Low to Intermediate HER2 Expression with
NeuVax Treatment Principal Investigator:Elizabeth A. Mittendorf Treatment Agent:GM-CSF; NeuVax Study Status:Open Study Description:The goal of this part of the clinical research study is to learn more about the
amounts of the HER2 protein in patients who had breast cancer using the Bond
Oracle HER2 IHC System.
Hybrid Mode
